License Transfer from Solasia to Lee’s Pharm for the Sales Promotion of Sancuso® and episil® in three cities in China
TOKYO & HONG KONG, June 30, 2022 ‐ Lee’s Pharmaceutical Holdings Limited (SEHK stock code: 0950, Headquarters: Hongkong, Executive Managing Director: Lee lalertsuphakun Wanee, hereinafter “Lee’s Pharm”) and Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) jointly announced today that Solasia and Lee’s Pharm have entered into a business transfer agreement for the rights of promoting, distributing and selling of Sancuso® and episil® in Beijing, Shanghai and Guangzhou in the People’s Republic of China.
TOKYO & HONG KONG, June 30, 2022 ‐ Lee’s Pharmaceutical Holdings Limited (SEHK stock code: 0950, Headquarters: Hongkong, Executive Managing Director: Lee lalertsuphakun Wanee, hereinafter “Lee’s Pharm”) and Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai,...